LivaNova PLC (LIVN) fair value analysis
Nasdaq · Updated 2026-10-19
LIVN price how computed
Forward Fair Value verdict
Fairly valuedLIVN is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $77.58
- Sector
- Healthcare
- 12-month range
- $49.57–$85.33
- Market cap
- $4.26B
- From 52-week high
- -9.1%
- Shares outstanding
- 54.9M
- Rank in Healthcare by discount to fair value
- #53 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
LivaNova PLC is a medical device company that develops and manufactures products for neuromodulation and cardiac surgery applications. The company operates globally with a presence in multiple countries across Europe, North America, and other regions.
LIVN currently ranks #53 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $4.26B
- P/E (trailing)
- 20x
- Revenue (TTM)
- $1.47B
- Net margin
- 12.8%
- EPS (TTM)
- $3.83
- Gross margin
- 70.1%
- Debt / equity
- 0.27
- Revenue growth (3-yr avg)
- 12.2%
- Shares outstanding
- 54.9M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 51 · neutral
- 50-day average
- $78.42
- 200-day average
- $72.04
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-04 (pre-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+6.3%)
2026-03 ▲ beat (+8.9%)
2025-12 ▲ beat (+6.1%)
2025-09 ▲ beat (+24.4%)
2025-06 ▲ beat (+20.7%)
2025-03 ▲ beat (+15.8%)
2024-12 ▲ beat (+1.2%)
2024-09 ▲ beat (+25.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 8 buy · 2 hold · 0 sell (10 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $90.5
- Target vs last price
- +16.7%
What our data shows for LIVN
- Our model validated 17 trailing price-to-earnings windows for LIVN, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $49.57–$85.33.
- The 14-day relative strength index sits at a neutral 51.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for LIVN
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent LIVN news
TickrTrends' derived news-sentiment signal for LIVN is currently leaning positive, computed from recent coverage.
- LivaNova PLC at Morgan Stanley Global Healthcare Conference Transcript (gurufocus.com, 2026-09-14)
TickrTrends take: LivaNova's participation in the Morgan Stanley Global Healthcare Conference provides an opportunity for investors to assess management commentary against the company's current fairly valued status in the healthcare sector. A valuation-focused reader should monitor whether management discusses competitive positioning, product pipeline developments, or market expansion plans that could justify a shift from the current fairly valued assessment. Any commentary on pricing dynamics, reimbursement trends, or margin trajectories in the neuromodulation and cardiac surgery markets would be particularly relevant to validating the current valuation judgment. - LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript (seekingalpha.com, 2026-09-14)
TickrTrends take: LivaNova's presentation at the Morgan Stanley healthcare conference provides an opportunity for investors to assess whether management commentary aligns with the company's current fairly valued status in the healthcare sector. A valuation-focused reader should monitor whether management discusses pricing power, market share trends, or capital allocation decisions that could justify any future revaluation. Statements about product adoption rates, competitive positioning, or guidance updates would be particularly relevant to evaluating whether the fairly valued assessment remains appropriate going forward. - GHO Capital appoints Vivid Sehgal as Operating Partner (manilatimes.net, 2026-09-08)
TickrTrends take: GHO Capital's appointment of Vivid Sehgal as Operating Partner represents a strategic move that could influence operational efficiency across its portfolio companies, including LIVN. Given TickrTrends' current assessment that LIVN is fairly valued, investors should monitor whether this leadership addition translates into measurable improvements in operational metrics or cost management that might validate the current valuation range. For a Healthcare sector company trading at fair value, operational enhancements driven by experienced leadership could be a key factor in determining whether the stock offers upside or maintains its current equilibrium.
What people are saying
Follow the LIVN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for LIVN showed improvement this week as the quality grade advanced from B to A, reflecting stronger operational fundamentals. The sector discount rank moved from 60th to 66th position, indicating a modest shift in relative valuation positioning within the Healthcare sector. The stock maintains a Fairly valued assessment at current levels.
- 2026-10-05 — LIVN's sector discount rank improved this week, moving from #67 to #60 among Healthcare sector stocks. This change indicates the company's valuation metrics have become more favorable relative to its peer group. The stock remains fairly valued according to current analysis.
- 2026-09-28 — TickrTrends' derived indicators for LIVN show movement in two areas this week. The 50/200-day trend state shifted from uptrend to mixed, while the sector discount rank improved from position 76 to position 67 within the Healthcare sector. The current valuation verdict remains Fairly valued.
- 2026-09-21 — # LIVN Weekly Indicator Summary TickrTrends' derived indicators for LIVN show a positive shift this week as the 50/200-day trend state improved from mixed to uptrend. The stock remains fairly valued according to current valuation metrics. This upward momentum in the intermediate-term trend represents a notable change in the technical picture for the healthcare company.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is LIVN stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), LIVN is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is LIVN's TickrTrends verdict?
LIVN's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does LIVN compare to other Healthcare stocks?
LIVN ranks #53 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is LIVN overbought or oversold?
LIVN's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does LIVN report earnings next?
LIVN's next earnings report is scheduled for 2026-11-04 (pre-market), per the published earnings calendar.
Does LIVN usually beat earnings estimates?
Over its last 8 reported quarters LIVN beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about LIVN?
Of 10 analysts covering LIVN, 8 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $90.5 (+16.7% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
LIVN vs ACHC · LIVN vs DHR · LIVN vs HCA · LIVN vs HCSG · LIVN vs IQV